Introduction {#s1}
============

The hemagglutinin (HA) and neuraminidase (NA) glycoproteins of influenza A virus (IAV) regulate viral attachment, entry, and release from cells. By binding terminal sialic acids, HA attaches virus to the cell surface to initiate the infectious cycle. By cleaving terminal sialic acids, NA releases virions from cells and substances that can interfere with viral attachment. Maximal viral fitness requires compatibility between the HA and NA, though the underlying mechanisms are incompletely understood.

Oseltamivir and zanamivir are NA active site inhibitors approved for use in humans [@pone.0015190-Kim1]. Mutants resistant to these drugs are readily selected in cell culture [@pone.0015190-Blick1], [@pone.0015190-McKimmBreschkin1], [@pone.0015190-Tai1], [@pone.0015190-Barnett1], suggesting that widespread use of these drugs has promoted the emergence of drug-resistant IAV strains in humans. This conclusion is supported by the temporal correlation between drug use and emergence of resistant mutants, and more directly by the isolation of NA mutants from chronically infected individuals treated with NA inhibitors [@pone.0015190-Memoli1]. By contrast, epidemiological studies failed to correlate drug use and resistance [@pone.0015190-Hauge1], [@pone.0015190-Dharan1], [@pone.0015190-Lackenby1], suggesting the participation of additional factors in selection.

NA-inhibitor resistant mutants are often compensated by changes in HA to restore viral fitness [@pone.0015190-McKimmBreschkin1], [@pone.0015190-Staschke1], [@pone.0015190-Yang1], [@pone.0015190-Blick2]. Many of these changes alter HA affinity for sialic acids. We recently reported that many of the amino substitutions in HA selected for escape from neutralizing monoclonal antibodies (mAbs) modulate HA avidity for host cells [@pone.0015190-Hensley1]. This prompts the question, do some of these substitutions provoke compensatory NA mutations to maximize viral fitness?

Results {#s2}
=======

We addressed this question by sequencing both HA and NA genes of 40 previously described anti-HA mAb escape mutants (mutants are named based on their selecting mAb). As reported [@pone.0015190-Caton1], each variant possessed the previously reported mutation leading to an amino acid substitution in their corresponding HA epitopes ([Table 1](#pone-0015190-t001){ref-type="table"}). Three of the 40 viruses, CV1, KV2, JV9, possessed a non-synonymous mutation in their NA genes at positions 274, 253, and 118, while the other 37 viruses had the *wt* sequence. Remarkably, for viruses with NA mutations, the HA substitutions form a clear pattern, since they are all located at the edge of the Sa antigenic site at the HA trimer interface, occupying positions K163T, K165E, and S167F ([**Fig. 1a**](#pone-0015190-g001){ref-type="fig"}). Each substitution in NA is located at a different NA residue ([**Fig. 1b**](#pone-0015190-g001){ref-type="fig"}).

![Compensatory NA mutations decrease NA activity.\
Three-dimensional view of HA trimer (a) and NA tetramer (b). Mutations found in individual viruses are in different colors (yellow = CV1, orange = KV2, green = JV9). Sialic acid (a) and the NA active site (b) are shown in red. (c) NA activities of viruses +/− Triton-X were determined using a colorimetric assay. The amount of glycoproteins incorporated in purified virions was determined by ELISA (d), western blots (e), and total protein blots (f). \*, p\<0.05 compared to PR8.](pone.0015190.g001){#pone-0015190-g001}
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###### Amino acid substitutions in HA mAb-selected variants.

![](pone.0015190.t001){#pone-0015190-t001-1}

  Vrus          HA          NA
  --------- ----------- -----------
  BV1          E156G    
  BV2          Q196R    
  BV6          G159D    
  BV11         Q192L    
  BV12         N193S    
  BV13         N193K    
  **CV1**    **K165E**   **H274N**
  CV5          P128S    
  CV8          N166K    
  CV9          P162L    
  CV10         L164Q    
  DV4          S140P    
  DV5          R224I    
  DV6          G143R    
  EV1          E156K    
  EV2          Q192R    
  EV8          E198G    
  HV1          G173E    
  JV3          S167Y    
  **JV9**    **S167F**   **V118I**
  **KV2**    **K163T**   **K253R**
  KV3          N129K    
  LV1          R78G     
  MV4          L75P     
  MV5          S79P     
  MV9          V77E     
  NV7          S145G    
  NV8          S145N    
  PV8          S160L    
  PV12         N129Y    
  PV20         E158V    
  RV2          E119G    
  RV3          E119K    
  RV7          L74P     
  SV5          I93T     
  SV7          G240R    
  WV7          I244T    
  WV10         V169A    
  WV11         G173R    
  WV15         G240E    

The correlation between alterations in this Sa subsite was confirmed by selecting escape mutants with a mixture of Sa-site specific mAbs. Once again, we obtained the K163T substitution, which was accompanied by a T191I NA substitution. Three other escape mutants characterized from the same selection experiment, N129K, N129D, and P162Q had no changes in NA gene sequence. It is nearly impossible statistically for the sequence change in NA that accompanies the K163T mutation to arise from chance in two separate selection experiments performed with different *wt* virus stocks. And it is highly unlikely that chance is responsible for NA sequence changes in the three adjacent Sa residues. Rather, we conclude that amino acid alterations in this region must reduce viral fitness in a manner that selects for compensatory non-synonymous mutations in the NA gene.

What are the effects of these NA substitutions on viral NA activity? CV1, KV2, and JV9 demonstrated reduced NA activity per virion relative to *wt* virus, as measured by hydrolysis of the NA substrate 2′-4-Methylumbelliferyl-alpha-D-N-acetyneuraminic acid ([**Fig. 1c**](#pone-0015190-g001){ref-type="fig"}). NA activity was reduced independently of HA physical proximity, as indicated by treating virus with Triton-X 100, a mild detergent that dissociates viral membranes, releasing the glycoproteins from virions. To address the extent to which the mutations reduced NA content per virion vs. intrinsically reduced NA activity, we quantified viral proteins present in purified virions by ELISA ([**Fig. 1d**](#pone-0015190-g001){ref-type="fig"}), western blots ([**Fig. 1e**](#pone-0015190-g001){ref-type="fig"}), and total protein stain ([**Fig. 1f**](#pone-0015190-g001){ref-type="fig"}), normalizing viral quantities by the amount of total protein present in a solution based assay. Reassuringly, the mutant viruses had indistinguishable levels of HA, NP, and M1. Surprisingly, two of the viruses (CV1 and KV2) exhibited reduced amounts of NA relative to other viral proteins. Thus, compensatory NA mutations diminish NA activity by intrinsic effects on enzyme activity and in two cases, by reducing NA incorporation per virion. We did not fully characterize the T191I NA mutation that emerged in our 2^nd^ selection experiments, but based on observation that this amino acid is located far from the NA active site we expect that this mutation likely affects NA activity by reducing NA incorporation into virions, rather than directly altering enzymatic activity.

NA mutations in CV1 (H274N), and JV9 (V118I) are in close proximity to the active site, while the mutation in KV2 (K253R) is a bit more distant. Substitutions at 253 are known to modulate NA antigenicity [@pone.0015190-Lentz1] and substitutions at residue 274 are known to modulate resistance to oseltamivir [@pone.0015190-Ives1], [@pone.0015190-GubarevaLarisa1], [@pone.0015190-Wang1]. Could the anti-HA mAb escape mutants exhibit altered NA drug sensitivity or antigenicity? We found that CV1 is dramatically resistant to zanamivir and more sensitive to oseltamivir ([**Fig. 2a--b**](#pone-0015190-g002){ref-type="fig"}). During the 2008--09 influenza season, the majority of H1N1 IAVs possessed the H274Y NA mutation which promoted oseltamivir resistance. The difference in drug sensitivity between CV1 and the 2008--09 seasonal variants (ie: more sensitive to oseltamivir versus more resistance to oseltamivir) is likely due to the specific amino acid substitution (H274N versus H274Y). Next, we examined NA antigenicity by measuring the binding affinity of anti-NA mAbs to the mutant viruses. Each of the mAbs used is specific for native NA and blocks NA activity using fetuin as a substrate. The mutation in CV1 resulted in a major NA antigenic change, as determined by reduced binding of 3 anti-NA mAbs ([**Fig. 2c**](#pone-0015190-g002){ref-type="fig"}). Taken together, these data demonstrate that IAVs can become resistant to NA inhibitors and exhibit altered NA antigenicity in response to Ab pressure on HA, in this particular circumstance, one region of the Sa site in the PR8 HA.

![Compensatory mutations alter NA drug sensitivity and antigenicity.\
Viruses were pre-incubated with zanamivir (a) or oseltamivir (b) and NA activity was determined. (c) Relative binding affinities of 3 control Abs (NA polyclonal Ab, HA mAb, and NP mAb) and 4 anti-NA mAbs were determined using an ELISA assay. Ab titrations were performed and relative K~d~ values were transformed into relative colors using the matrix2png software. Black indicates high binding affinity and white indicates low binding affinity.](pone.0015190.g002){#pone-0015190-g002}

Discussion {#s3}
==========

Recent findings indicate that certain mutations in NA allow the molecule to become promiscuous for additional mutations that confer drug resistance [@pone.0015190-Bloom1]. Our findings have similar implications for understanding NA evolution in man: anti-HA Ab driven escape can possibly select for compensatory changes in NA that alter drug resistance. This phenomenon provides a potential explanation for the poor correlation between NA inhibitor use and emergence of drug-resistant strains. Another important implication from our studies is that a significant amount of NA antigenic drift may be a byproduct of HA antigenic drift.

We are uncertain of the underlying mechanism that promotes selection of mutated NA in our experimental system. There are no simple correlations between HA receptor binding avidity and the emergence of compensatory NA mutations. For example, the HA mutation, K165E, increases receptor binding avidity whereas the mutations, K163T or S167F, do not apparently alter receptor binding avidity [@pone.0015190-Hensley1]. It should be noted that these binding assays measure overall avidity to many different glycans expressed on red blood cells, and an intriguing possibility is that NA mutations arise to restore balance to the binding/cleavage to specific glycans. Further elucidation of mechanisms that promote NA compensatory mutations may facilitate early identification of drug resistant IAV strains in the human population.

Materials and Methods {#s4}
=====================

Sequencing {#s4a}
----------

RNA was extracted from virus stocks using a QiAmp viral RNA mini kit. For each RNA extraction, we started with 140 ul of virus in allantoic fluid. cDNA was made and HA and NA genes were amplified by PCR. Sequencing was performed on an AppliedBiosystem DNA analyzer.

Enzyme Activity {#s4b}
---------------

NA activity was determined as previously described [@pone.0015190-Potier1] with slight modifications. For these assays, we used purified viruses. Virus amounts were adjusted based on NA levels as determined by ELISA (for each assay, this corresponded to approximately 50--100 HAUs of virus/sample). Viruses were diluted in assay buffer (33 mM MES (pH 6.5), 4 mM CaCl2) and 200 uM of 2′-4-Methylumbelliferyl-alpha-D-N-acetyneuraminic acid was added. Samples were placed in black flat bottom plates at 37°C and O.D. (Ex = 365 nm; Em = 450 nm) readings were recorded every minute for 30 minutes. Data are expressed as the rate of enzymatic activity (relative vmax). For some experiments, viruses were pre-incubated with 1% Triton-X to disrupt viral membranes. For other experiments, viruses were pre-incubated for 1 hour at 37°C with increasing amounts of oseltamivir or zanamivir.

ELISAs {#s4c}
------

For glycoprotein quantification studies, plates were coated with 150 ng/mL of purified virions diluted in PBS (as determined using the BioRad DC protein assay) overnight at 4°C and then blocked for 1 hour at room temperature with PBS-FBS. A saturating amount of either a purified HA mAb (CM1) (diluted 1∶100) or polyclonal rabbit anti-NA Ab mixture (diluted 1∶200) was then added and allowed to incubate for 2 hours at room temperature. Anti-mouse or anti-rabbit HRP (diluted 1∶4000) was then added and allowed to incubate for 1 hour at room temperature. TMB substrate was added and the reaction was stopped with HCL and O.D.s were measured at 450 nm. For mAb escape experiments, plates were coated overnight at 4°C with viruses that were normalized based on NA amount (this corresponds to ∼50--100 HAU/well). The ELISAs were carried out as described above except decreasing amounts of mAb or polyclonal Abs were used. Based on these Ab titrations, K~d~ were calculated and relative binding affinities based on these K~d~ were graphed. For this set of experiments, data were graphed using the previously described matrix2png software [@pone.0015190-Pavlidis1]. Between all ELISA steps, plates were washed with PBS-tween.

Immunoblots {#s4d}
-----------

Purified virions (3 ug as determined using BioRad DC protein assay) were mixed with SDS-PAGE buffer and run on a 12% SDS-PAGE gel and the gels were blotted on nitrocellulose. These membranes were then incubated with an anti-HA mAb (CM1) (hybridoma supernatant diluted 1∶1) and rabbit polyclonal anti-NA Abs (diluted 1∶1000) and then with infrared dye coupled secondary Abs (Donkey anti-mouse IR Dye 800 and Donkey anti-rabbit IR Dye 680---each diluted 1∶10,000). Blots were analyzed using an Odyssey imaging system. For other experiments, non-reduced samples were run on a 12% SDS-PAGE gel and then stained with Syproruby to visualize total protein content.
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